Cargando…

Clinical and cognitive improvement following full-spectrum, high-cannabidiol treatment for anxiety: open-label data from a two-stage, phase 2 clinical trial

BACKGROUND: Evidence suggests cannabidiol (CBD) has anxiolytic properties, indicating potential for novel treatment strategies. However, few clinical trials of CBD-based products have been conducted, and none thus far have examined the impact of these products on cognition. METHODS: For the open-lab...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dahlgren, Mary Kathryn, Lambros, Ashley M., Smith, Rosemary T., Sagar, Kelly A., El-Abboud, Celine, Gruber, Staci A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9628346/ https://www.ncbi.nlm.nih.gov/pubmed/36352103 http://dx.doi.org/10.1038/s43856-022-00202-8

Ejemplares similares

Urinary Tetrahydrocannabinol After 4 Weeks of a Full-Spectrum, High-Cannabidiol Treatment in an Open-label Clinical Trial
por: Dahlgren, M. Kathryn, et al.
Publicado: (2020)

A survey of medical cannabis use during perimenopause and postmenopause
por: Dahlgren, M. Kathryn, et al.
Publicado: (2022)

Increased White Matter Coherence Following Three and Six Months of Medical Cannabis Treatment
por: Dahlgren, Mary Kathryn, et al.
Publicado: (2022)

CannaCount: an improved metric for quantifying estimates of maximum possible cannabinoid exposure
por: Lambros, Ashley M., et al.
Publicado: (2023)

Made from concentrate? A national web survey assessing dab use in the United States
por: Sagar, Kelly A., et al.
Publicado: (2018)

Assessing Cannabis Use Disorder in Medical Cannabis Patients: Interim Analyses from an Observational, Longitudinal Study
por: Sagar, Kelly A., et al.
Publicado: (2021)

Recreational cannabis use impairs driving performance in the absence of acute intoxication
por: Dahlgren, M. Kathryn, et al.
Publicado: (2020)

The Grass Might Be Greener: Medical Marijuana Patients Exhibit Altered Brain Activity and Improved Executive Function after 3 Months of Treatment
por: Gruber, Staci A., et al.
Publicado: (2018)

Splendor in the Grass? A Pilot Study Assessing the Impact of Medical Marijuana on Executive Function
por: Gruber, Staci A., et al.
Publicado: (2016)

Worth the wait: effects of age of onset of marijuana use on white matter and impulsivity
por: Gruber, Staci A., et al.
Publicado: (2013)

The Impact of Micronutrient Fortified Foods on Cognitive Functioning among Low-Income Children: A Pilot and Feasibility Study
por: Cohen, Juliana F. W., et al.
Publicado: (2020)

Joint Effects: A Pilot Investigation of the Impact of Bipolar Disorder and Marijuana Use on Cognitive Function and Mood
por: Sagar, Kelly A., et al.
Publicado: (2016)

Cannabidiol as a personalized treatment for anxiety: clinical cases in Mexico
por: Ortiz Rios, Flor Cristina, et al.
Publicado: (2022)

Long‐term cannabidiol treatment in patients with Dravet syndrome: An open‐label extension trial
por: Devinsky, Orrin, et al.
Publicado: (2018)

Cannabidiol in patients with Lennox‐Gastaut syndrome: Interim analysis of an open‐label extension study
por: Thiele, Elizabeth, et al.
Publicado: (2019)

CANNABIDIOL- PROVOKES OR TREATS ANXIETY DISORDERS?
por: Arshad, H., et al.
Publicado: (2023)

Citicoline Treatment Improves Measures of Impulsivity and Task Performance in Chronic Marijuana Smokers: A Pilot BOLD fMRI Study
por: Gruber, Staci A., et al.
Publicado: (2015)

Cannabidiol Cigarettes as Adjunctive Treatment for Psychotic Disorders – A Randomized, Open-Label Pilot-Study
por: Köck, Patrick, et al.
Publicado: (2021)

Therapeutic Effects of Prolonged Cannabidiol Treatment on Psychological Symptoms and Cognitive Function in Regular Cannabis Users: A Pragmatic Open-Label Clinical Trial
por: Solowij, Nadia, et al.
Publicado: (2018)

Long‐term cannabidiol treatment for seizures in patients with tuberous sclerosis complex: An open‐label extension trial
por: Thiele, Elizabeth A., et al.
Publicado: (2021)

Dermatological evaluation in dogs with atopic dermatitis treated with full-spectrum high cannabidiol oil: a pre study part 1
por: Mariga, Carollina, et al.
Publicado: (2023)

Decreased Amygdalar Activation to NSSI-Stimuli in People Who Engage in NSSI: A Neuroimaging Pilot Study
por: Hooley, Jill M., et al.
Publicado: (2020)

Label accuracy of unregulated cannabidiol (CBD) products: measured concentration vs. label claim
por: Johnson, Erin, et al.
Publicado: (2022)

Slow Titration of Cannabidiol Add-On in Drug-Resistant Epilepsies Can Improve Safety With Maintained Efficacy in an Open-Label Study
por: D'Onofrio, Gianluca, et al.
Publicado: (2020)

Effect of Cannabidiol on Interictal Epileptiform Activity and Sleep Architecture in Children with Intractable Epilepsy: A Prospective Open-Label Study
por: Klotz, Kerstin A., et al.
Publicado: (2021)

Contemplating cannabis? The complex relationship between cannabinoids and hepatic metabolism resulting in the potential for drug-drug interactions
por: Smith, Rosemary T., et al.
Publicado: (2023)

Cannabidiol in Treatment of Autism Spectrum Disorder: A Case Study
por: Ma, Lucy, et al.
Publicado: (2022)

Δ9-THC Intoxication by Cannabidiol-Enriched Cannabis Extract in Two Children with Refractory Epilepsy: Full Remission after Switching to Purified Cannabidiol
por: Crippa, José A. S., et al.
Publicado: (2016)

A systematic review of cannabidiol dosing in clinical populations
por: Millar, S.A., et al.
Publicado: (2019)

Preclinical and Clinical Evidence Supporting Use of Cannabidiol in Psychiatry
por: Calapai, Gioacchino, et al.
Publicado: (2019)

Cannabidiol Drugs Clinical Trial Outcomes and Adverse Effects
por: Pauli, Christopher S., et al.
Publicado: (2020)

Cannabidiol Regulation of Learned Fear: Implications for Treating Anxiety-Related Disorders
por: Jurkus, Regimantas, et al.
Publicado: (2016)

Anxiolytic Effects of Repeated Cannabidiol Treatment in Teenagers With Social Anxiety Disorders
por: Masataka, Nobuo
Publicado: (2019)

Cannabidiol treatment in an adolescent with multiple substance abuse, social anxiety and depression
por: Laczkovics, Clarissa, et al.
Publicado: (2020)

Clinical effectiveness and safety of escitalopram and desvenlafaxine in patients of depression with anxiety: A randomized, open-label controlled trial
por: Maity, Nabakumar, et al.
Publicado: (2014)

Reducing the anxiety of patients undergoing an oral biopsy by means of graphic novels: an open-label randomized clinical trial
por: Bazzano, Monica, et al.
Publicado: (2023)

Autism Spectrum Disorder and Cannabidiol: Have We Seen This Movie Before?
por: Salgado, Carlos A., et al.
Publicado: (2018)

Cannabidiol in clinical and preclinical anxiety research. A systematic review into concentration–effect relations using the IB-de-risk tool
por: Kwee, Caroline MB, et al.
Publicado: (2022)

Translating Endocannabinoid Biology into Clinical Practice: Cannabidiol for Stroke Prevention
por: Scharf, Eugene L.
Publicado: (2017)

Pharmacokinetics, Safety, and Clinical Efficacy of Cannabidiol Treatment in Osteoarthritic Dogs
por: Gamble, Lauri-Jo, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_4bum73msa9bs9ujnpe5r73fubi